These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28613442)

  • 21. CMV-specific Cell-mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at Risk of Late-onset CMV Infection Regardless the Type of Induction Therapy.
    Jarque M; Melilli E; Crespo E; Manonelles A; Montero N; Torras J; Cruzado JM; Luque S; Gil-Vernet S; Grinyó JM; Bestard O
    Transplantation; 2018 Nov; 102(11):e472-e480. PubMed ID: 30130330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
    Singh N; Wannstedt C; Keyes L; Wagener MM; Cacciarelli TV
    Liver Transpl; 2005 Jun; 11(6):700-4. PubMed ID: 15915496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased incidence of acute rejection without increased incidence of cytomegalovirus (CMV) infection in kidney transplant recipients receiving rabbit anti-thymocyte globulin without CMV prophylaxis - a cohort single-center study.
    de Paula MI; Bowring MG; Shaffer AA; Garonzik-Wang J; Bessa AB; Felipe CR; Cristelli MP; Massie AB; Medina-Pestana J; Segev DL; Tedesco-Silva H
    Transpl Int; 2021 Feb; 34(2):339-352. PubMed ID: 33314321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High incidence of clinically significant cytomegalovirus infection in CMV D+/R+ lung transplant recipients receiving 3 months of antiviral prophylaxis.
    Kabbani D; Hirji A; Hernandez C; Malhi H; Mabilangan C; Chandrarathne S; Halloran K; Weinkauf J; Kapasi A; Lien D; Preiksaitis J; Cervera C
    Transpl Infect Dis; 2019 Aug; 21(4):e13094. PubMed ID: 30985048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.
    Meije Y; Fortún J; Len Ó; Aguado JM; Moreno A; Cisneros JM; Gurguí M; Carratalà J; Muñoz P; Montejo M; Blanes M; Bou G; Pérez JL; Torre-Cisneros J; Ramos A; Pahissa A; Gavaldà J;
    Transpl Infect Dis; 2014 Jun; 16(3):387-96. PubMed ID: 24807640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial.
    Carrier M; Leblanc MH; Perrault LP; White M; Doyle D; Beaudoin D; Guertin MC
    J Heart Lung Transplant; 2007 Mar; 26(3):258-63. PubMed ID: 17346628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk Factors of Cytomegalovirus Disease in Kidney Transplant Recipients: A Single-Center Study in Thailand.
    Chiasakul T; Townamchai N; Jutivorakool K; Chancharoenthana W; Thongprayoon C; Watanatorn S; Avihingsanon Y; Praditpornsilpa K; Srisawat N
    Transplant Proc; 2015 Oct; 47(8):2460-4. PubMed ID: 26518951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction.
    Luan FL
    Transplant Proc; 2013; 45(1):175-7. PubMed ID: 23267799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytomegalovirus disease in renal transplant recipients: a single-center experience.
    Cavdar C; Celtik A; Saglam F; Sifil A; Atila K; Celik A; Tosun P; Olmuscelik O; Bora S; Gulay H; Camsari T
    Ren Fail; 2008; 30(5):503-6. PubMed ID: 18569930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage.
    Santos CA; Brennan DC; Saeed MJ; Fraser VJ; Olsen MA
    Clin Transplant; 2016 Apr; 30(4):435-44. PubMed ID: 26841129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus.
    Devresse A; Leruez-Ville M; Scemla A; Avettand-Fenoel V; Morin L; Lebreton X; Tinel C; Amrouche L; Lamhaut L; Timsit MO; Zuber J; Legendre C; Anglicheau D
    Transpl Infect Dis; 2018 Apr; 20(2):e12846. PubMed ID: 29360195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomegalovirus infection in high-risk kidney transplant recipients receiving thymoglobulin induction-a single-center experience.
    Puttarajappa C; Bhattarai M; Mour G; Shen C; Sood P; Mehta R; Shah N; Tevar AD; Humar A; Wu C; Hariharan S
    Clin Transplant; 2016 Sep; 30(9):1159-64. PubMed ID: 27423138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
    J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of induction therapy on cytomegalovirus infection and post-transplant outcomes in pediatric heart transplant recipients receiving routine antiviral prophylaxis.
    Zang S; Zhang X; Niu J; Das BB
    Clin Transplant; 2023 Jan; 37(1):e14836. PubMed ID: 36259556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
    Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
    Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
    Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Routine induction therapy in living donor liver transplantation prevents rejection but may promote recurrence of hepatitis C.
    Ghanekar A; Kashfi A; Cattral M; Selzner N; McGilvray I; Selzner M; Renner E; Lilly L; Levy G; Grant D; Greig P
    Transplant Proc; 2012 Jun; 44(5):1351-6. PubMed ID: 22664014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
    Brady RL; Green K; Frei C; Maxwell P
    Transpl Infect Dis; 2009 Apr; 11(2):106-11. PubMed ID: 19054381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of recipient age on mortality among Cytomegalovirus (CMV)-seronegative lung transplant recipients with CMV-seropositive donors.
    Belga S; Hussain S; Avery RK; Nauroz Z; Durand CM; King EA; Massie A; Segev DL; Connor AE; Bush EL; Levy RD; Shah P; Werbel WA
    J Heart Lung Transplant; 2024 Apr; 43(4):615-625. PubMed ID: 38061469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.